Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102766 | 0.92 | CYP19A1 (0.55) | CYP19A1CYP17A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL12336931 | 0.91 | CYP11B1 (0.46) | CYP19A1CYP17A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL12336821 | 0.91 | CYP19A1 (0.52) | CYP19A1CYP17A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL12336936 | 0.87 | CYP11B1 (0.45) | CYP19A1CYP17A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL10102742 | 0.83 | CYP11B1 (0.46) | CYP19A1CYP17A1CYP11B1CYP11B2KDM4E | |
| SCHEMBL669277 | 0.83 | CYP19A1 (0.52) | CYP19A1CYP17A1KDM4ECYP26A1CYP3A4 | |
| SCHEMBL9192257 | 0.82 | KDM4E (0.44) | CYP17A1CYP11B1CYP11B2KDM4ECYP26A1 | |
| SCHEMBL10102768 | 0.82 | CYP19A1 (0.55) | CYP19A1KDM4ECYP26A1CYP3A4CYP2C8 | |
| SCHEMBL10102763 | 0.78 | CYP19A1 (0.57) | CYP19A1KDM4ECYP26A1CYP3A4CYP2C8 | |
| SCHEMBL12337074 | 0.77 | CYP19A1 (0.48) | CYP19A1CYP17A1CYP26A1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524714-B2 | 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-09-22 | — | — | US | disclosed |
| US-7928104-B2 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928104-B2 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249099-A1 | Enhances sensitivity to radiotherapy and chemotherapy; synergistic; hydrolysis of a 2-methoxyquinoline or 2-methoxyquinoxaline; cyclization of a N-phenyl phenylacrylamide; or condensation of an o-benzenediamine with a keto-ester; preferred oxalate salt; side effect reduction | PARP1, PARP2, PARP3 | CYP19A1 470/4885CYP17A1 1630/4885CYP11B1 974/4885 |
| US-20110230492-A1 | 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | CYP19A1 933/4885CYP17A1 2546/4885CYP11B1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.